JLP 2002
Alternative Names: JLP-2002; JLP-2002ALatest Information Update: 09 Feb 2022
At a glance
- Originator Jeil Pharmaceutical
- Class Antispasmodics; Urologics
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Overactive bladder
Most Recent Events
- 26 May 2021 Jeil Pharmaceutical completes a phase I pharmacokinetics and safety trial in Healthy volunteers in South Korea in May 2021 (NCT04914221)
- 13 Mar 2021 Phase-I clinical trials in Overactive bladder (In adults, In volunteers) in South Korea (PO) in March 2021 (NCT04914221)
- 21 May 2020 Phase-III clinical trials in Overactive bladder in South Korea (PO) (NCT04917315)